ProtaGene, a leading global contract research organization (CRO) dedicated to advanced analytics for biologics and cell and gene therapies, today announced additional investment from Ampersand Capital Partners. Given the critical […]
Autor: Firma ProtaGene
Confronting Molecular Bioanalysis Challenges in Gene Therapy Development
As the gene therapy sector continues to mature, regulators’ expectations for more robust product understanding are growing. It’s exciting to be part of today’s gene therapy development community; however, three […]
Navigating CMC Challenges in NBE and Therapeutic Antibody Development
In April 2021, the FDA approved the 100th monoclonal antibody as a therapeutic entity, a milestone that took 35 years to reach. As of the fall of 2022, the FDA […]
ProtaGene Appoints New Scientific and Commercial Leadership to Support Evolving Needs of Biologic and Cell & Gene Therapy Innovators
ProtaGene GmbH, a leading global contract research organization focused on advanced analytics in biologics and cell and gene therapy, announced today the appointment of Jennifer Chadwick, Ph.D., as Chief Scientific […]
Foundation for the Industry’s Next-stage Innovation and Growth
ProtaGene is thrilled to announce the planned opening of our brand-new, state-of-the-art lab and office headquarters in the Burlington BioCenter, located in Boston’s rapidly growing biotechnology hub. Our expanded footprint […]